evinacumab   Click here for help

GtoPdb Ligand ID: 8717

Synonyms: evinacumab-dgnb | Evkeeza® | REGN1500
Approved drug
evinacumab is an approved drug (FDA (2021))
Compound class: Antibody
Comment: Evinacumab is a fully human monoclonal antibody targeting angiopoietin-like 3 (ANGPTL3). Due to its role in lipid metabolism, ANGPTL3 is being investigated as a potential molecular target for the treatment of hypertriglyceridemia.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record.
A BLAST search of patented peptide sequences reveals that the heavy chain variable domain of evinacumab is identical to SEQ ID: NO 66 from patent US9018356 B2 [3], and the light chain variable region is identical to SEQ ID: NO 74 from the same patent (this heavy/light chain combination corresponds to antibody identifier H4H1276S).

Evinacumab utilises a different molecular mechanism compared to Regeneron's already approved anti-hyperlipidemic drug alirocumab (targets proprotein convertase subtilisin/kexin type 9).
Bioactivity Comments
The affinity value in the table below represents antibody binding to full length human ANGPTL3. The corresponding Kd value for binding to the N-terminal coiled-coil domain of ANGPTL3 is reported as 0.66nM [3].
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
angiopoietin-like 3 Primary target of this compound Hs Antibody Binding 8.9 pKd - 3
pKd 8.9 (Kd 1.35x10-9 M) [3]